MA53981A - Récepteurs de lymphocytes t de ny-eso-1 et leurs procédés d'utilisation - Google Patents
Récepteurs de lymphocytes t de ny-eso-1 et leurs procédés d'utilisationInfo
- Publication number
- MA53981A MA53981A MA053981A MA53981A MA53981A MA 53981 A MA53981 A MA 53981A MA 053981 A MA053981 A MA 053981A MA 53981 A MA53981 A MA 53981A MA 53981 A MA53981 A MA 53981A
- Authority
- MA
- Morocco
- Prior art keywords
- eso
- methods
- lymphocyte receptors
- lymphocyte
- receptors
- Prior art date
Links
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 title 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4269—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749194P | 2018-10-23 | 2018-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53981A true MA53981A (fr) | 2021-09-01 |
Family
ID=68582342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053981A MA53981A (fr) | 2018-10-23 | 2019-10-23 | Récepteurs de lymphocytes t de ny-eso-1 et leurs procédés d'utilisation |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12466870B2 (fr) |
| EP (1) | EP3870602A1 (fr) |
| JP (1) | JP7569313B2 (fr) |
| KR (1) | KR102933479B1 (fr) |
| CN (1) | CN113454110B (fr) |
| AU (2) | AU2019364367B2 (fr) |
| CA (1) | CA3117539A1 (fr) |
| EA (1) | EA202191107A1 (fr) |
| MA (1) | MA53981A (fr) |
| WO (1) | WO2020086647A1 (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240007775A (ko) | 2016-12-08 | 2024-01-16 | 이매틱스 바이오테크놀로지스 게엠베하 | T 세포 수용체 및 이를 사용하는 면역 요법 |
| WO2020086647A1 (fr) | 2018-10-23 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Récepteurs de lymphocytes t de ny-eso-1 et leurs procédés d'utilisation |
| WO2020263830A1 (fr) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Protéines de fusion flt3l-fc et procédés d'utilisation |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| CA3188143A1 (fr) * | 2020-06-25 | 2021-12-30 | The Methodist Hospital | Recepteurs de lymphocytes t specifiques d'antigenes et recepteurs antigeniques chimeriques, et methodes d'utilisation dans la modulation de la signalisation immunitaire pour l'imm unotherapie anticancereuse |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| JP7526079B2 (ja) * | 2020-11-13 | 2024-07-31 | Ykk Ap株式会社 | 樹脂枠の製造方法、樹脂枠 |
| TW202246511A (zh) * | 2021-02-25 | 2022-12-01 | 美商萊爾免疫藥物股份有限公司 | 靶向ny-eso-1之增強免疫細胞療法 |
| WO2022245671A1 (fr) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Méthodes d'utilisation de protéines de fusion flt3l-fc |
| CN113912701B (zh) * | 2021-10-14 | 2024-07-19 | 深圳大学总医院 | Tcr及其在诊断/治疗中的应用 |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| EP4449418A4 (fr) * | 2021-12-15 | 2025-11-19 | 3T Biosciences Inc | Méthodes et systèmes d'évaluation de récepteurs et d'antigènes de cellules immunitaires |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| US12584107B2 (en) | 2022-01-20 | 2026-03-24 | 3T Biosciences, Inc. | T cell receptor (TCR) compositions and methods for optimizing antigen reactive T-cells |
| US20230287080A1 (en) * | 2022-01-20 | 2023-09-14 | 3T Biosciences, Inc. | T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (fr) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| KR20250028371A (ko) | 2022-07-01 | 2025-02-28 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| CN121620513A (zh) | 2023-07-26 | 2026-03-06 | 吉利德科学公司 | Parp7抑制剂 |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (fr) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Inhibiteurs azaspiro de wrn |
| WO2025245003A1 (fr) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| IL79289A (en) | 1985-07-05 | 1992-01-15 | Whitehead Biomedical Inst | Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| ATE117375T1 (de) | 1987-09-11 | 1995-02-15 | Whitehead Biomedical Inst | Transduktionsveränderte fibroblasten und ihre anwendung. |
| JP2914692B2 (ja) | 1987-12-11 | 1999-07-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 内皮細胞の遺伝子修飾 |
| WO1989007136A2 (fr) | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Hepatocytes modifies et leurs utilisations |
| ES2096750T3 (es) | 1990-10-31 | 1997-03-16 | Somatix Therapy Corp | Vectores retroviricos utiles para la terapia genica. |
| WO1999060120A2 (fr) | 1998-05-19 | 1999-11-25 | Avidex Limited | Recepteur de lymphocyte t soluble |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| ATE417065T1 (de) | 2004-05-19 | 2008-12-15 | Medigene Ltd | Hochaffiner ny-eso-t-zellen-rezeptor |
| US9281917B2 (en) | 2007-01-03 | 2016-03-08 | Nokia Technologies Oy | Shared control channel structure |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2852613B1 (fr) * | 2012-05-22 | 2019-01-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Récepteurs murins des lymphocytes t anti-ny-eso-1 |
| EP3404111A1 (fr) | 2013-03-13 | 2018-11-21 | Health Research, Inc. | Compositions et procédés d'utilisation de récepteurs de lymphocytes t recombinants pour diriger la reconnaissance d'antigène tumoral |
| AU2014301777B2 (en) | 2013-06-26 | 2017-03-30 | Xlifesc, Ltd. | High-stability T-cell receptor and preparation method and application thereof |
| PL228457B1 (pl) | 2013-08-30 | 2018-03-30 | Univ Jagiellonski | Tomograf hybrydowy TOF-PET/CT |
| IL297773B2 (en) | 2014-11-17 | 2024-07-01 | Adicet Bio Inc | Engineered gamma delta t-cells |
| CN105985427A (zh) * | 2015-02-06 | 2016-10-05 | 广州市香雪制药股份有限公司 | 高亲和力ny-eso t细胞受体 |
| EP4248744A3 (fr) | 2015-04-06 | 2023-12-27 | Regeneron Pharmaceuticals, Inc. | Réponses immunitaires médiées par des cellules t humanisées dans des animaux non humains |
| CN106188275A (zh) * | 2015-05-06 | 2016-12-07 | 广州市香雪制药股份有限公司 | 识别ny-eso-1抗原短肽的t细胞受体 |
| US20190119350A1 (en) * | 2015-09-09 | 2019-04-25 | Immune Design Corp. | Ny-eso-1 specific tcrs and methods of use thereof |
| CN106432475B (zh) * | 2015-10-19 | 2018-06-01 | 广东香雪精准医疗技术有限公司 | 高亲和力ny-eso t细胞受体 |
| GB201522592D0 (en) | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| GB201616238D0 (en) * | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
| JP2020503883A (ja) * | 2017-01-13 | 2020-02-06 | アジェナス インコーポレイテッド | Ｎｙ−ｅｓｏ−１に結合するｔ細胞受容体およびその使用方法 |
| CN108456247A (zh) * | 2017-02-20 | 2018-08-28 | 上海恒润达生生物科技有限公司 | 靶向ny-eso-1的t细胞受体及其用途 |
| WO2020086647A1 (fr) | 2018-10-23 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Récepteurs de lymphocytes t de ny-eso-1 et leurs procédés d'utilisation |
-
2019
- 2019-10-23 WO PCT/US2019/057543 patent/WO2020086647A1/fr not_active Ceased
- 2019-10-23 EA EA202191107A patent/EA202191107A1/ru unknown
- 2019-10-23 MA MA053981A patent/MA53981A/fr unknown
- 2019-10-23 EP EP19804919.9A patent/EP3870602A1/fr active Pending
- 2019-10-23 CN CN201980085431.3A patent/CN113454110B/zh active Active
- 2019-10-23 AU AU2019364367A patent/AU2019364367B2/en active Active
- 2019-10-23 KR KR1020217015373A patent/KR102933479B1/ko active Active
- 2019-10-23 US US17/287,643 patent/US12466870B2/en active Active
- 2019-10-23 JP JP2021522096A patent/JP7569313B2/ja active Active
- 2019-10-23 CA CA3117539A patent/CA3117539A1/fr active Pending
-
2025
- 2025-05-23 AU AU2025203827A patent/AU2025203827A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020086647A1 (fr) | 2020-04-30 |
| CN113454110B (zh) | 2024-07-02 |
| AU2019364367A1 (en) | 2021-05-27 |
| AU2025203827A1 (en) | 2025-06-12 |
| AU2019364367B2 (en) | 2025-02-27 |
| EA202191107A1 (ru) | 2021-09-17 |
| WO2020086647A8 (fr) | 2020-05-28 |
| EP3870602A1 (fr) | 2021-09-01 |
| CA3117539A1 (fr) | 2020-04-30 |
| US20210403527A1 (en) | 2021-12-30 |
| CN113454110A (zh) | 2021-09-28 |
| KR20210093908A (ko) | 2021-07-28 |
| JP2022505679A (ja) | 2022-01-14 |
| JP7569313B2 (ja) | 2024-10-17 |
| KR102933479B1 (ko) | 2026-03-04 |
| US12466870B2 (en) | 2025-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53981A (fr) | Récepteurs de lymphocytes t de ny-eso-1 et leurs procédés d'utilisation | |
| MA56548A (fr) | Récepteurs de lymphocytes t mage-a4 et leurs procédés d'utilisation | |
| EP3947688A4 (fr) | Récepteurs de lymphocytes t et leurs procédés d'utilisation | |
| EP3737689A4 (fr) | Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation | |
| EP3935172A4 (fr) | Récepteurs de lymphocytes t et leurs procédés d'utilisation | |
| EP3436079A4 (fr) | Récepteurs antigéniques chimériques et récepteurs de lymphocytes t et leurs procédés d'utilisation | |
| EP3935176A4 (fr) | Récepteurs de lymphocytes t et leurs procédés d'utilisation | |
| EP3565829A4 (fr) | Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation | |
| MA47265A (fr) | Récepteurs de lymphocytes t qui se lient à ny-eso-1 et méthodes d'utilisation de ces derniers | |
| MA55136A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
| EP3634430A4 (fr) | Agents multibiotiques et procédés d'utilisation de ceux-ci | |
| MA51848A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52496A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| EP3797123A4 (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
| EP4072576A4 (fr) | Orthologues de l'il-2 et procédés d'utilisation | |
| EP3423108A4 (fr) | Polypeptides multimères modulateurs des lymphocytes t et leurs procédés d'utilisation | |
| MA56191A (fr) | Inhibiteurs de l'autophagie à base d'amide d'aminopyrimidine et leurs procédés d'utilisation | |
| MA53015A (fr) | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés | |
| MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
| EP3935079A4 (fr) | Polypeptides de présentation d'antigènes modulateurs de lymphocytes t et leurs procédés d'utilisation | |
| EP3897701A4 (fr) | Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation | |
| EP3935171A4 (fr) | Récepteurs de lymphocytes t et leurs procédés d'utilisation | |
| EP3846808A4 (fr) | Inhibiteurs de papd5 et leurs procédés d'utilisation | |
| EP3873939A4 (fr) | Anticorps anti-cd79b et récepteurs d'antigènes chimériques et leurs procédés d'utilisation |